![David W. Dube](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David W. Dube
President at Stock Car Stocks Mutual Fund, Inc.
Profile
Mr. David W.
Dube, CPA, is a Director at Glycogenesys, Inc., President at Stock Car Stocks Mutual Fund, Inc., and Chairman & Chief Financial Officer at Swan Group of Cos., Inc. He is on the Board of Directors at Glycogenesys, Inc.
Mr. Dube also served on the board at CNE Group, Inc.
He received his undergraduate degree from Suffolk University, a graduate degree from Suffolk University, and a graduate degree from Bentley University.
David W. Dube active positions
Companies | Position | Start |
---|---|---|
Stock Car Stocks Mutual Fund, Inc. | President | 22/12/2009 |
Former positions of David W. Dube
Companies | Position | End |
---|---|---|
CNE Group, Inc. | Director/Board Member | 13/11/2005 |
SWAN GROUP OF COMPANIES, INC. | Chairman | - |
Glycogenesys, Inc.
![]() Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Director/Board Member | - |
Training of David W. Dube
Suffolk University | Graduate Degree |
Bentley University | Graduate Degree |
Experiences
Positions held
Linked companies
Private companies | 4 |
---|---|
CNE Group, Inc. | Commercial Services |
Glycogenesys, Inc.
![]() Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
Stock Car Stocks Mutual Fund, Inc. | Miscellaneous |
Swan Group of Cos., Inc.
![]() Swan Group of Cos., Inc. Wholesale DistributorsDistribution Services Swan Group of Companies, Inc. engages in the manufacture and sale of smokeless cigarette products. The company was founded on January 24, 1996 and is headquartered in Largo, FL. | Distribution Services |
- Stock Market
- Insiders
- David W. Dube